Regulus Therapeutics Inc (RGLS)
2.77
-0.03
(-1.07%)
USD |
NASDAQ |
Apr 15, 16:00
2.77
0.00 (0.00%)
After-Hours: 20:00
Regulus Therapeutics Enterprise Value: 158.91M for April 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 15, 2024 | 158.91M |
| April 12, 2024 | 160.87M |
| April 11, 2024 | 159.57M |
| April 10, 2024 | 149.09M |
| April 09, 2024 | 154.33M |
| April 08, 2024 | 152.36M |
| April 05, 2024 | 143.85M |
| April 04, 2024 | 142.54M |
| April 03, 2024 | 148.44M |
| April 02, 2024 | 155.64M |
| April 01, 2024 | 160.87M |
| March 28, 2024 | 166.11M |
| March 27, 2024 | 166.11M |
| March 26, 2024 | 163.82M |
| March 25, 2024 | 162.18M |
| March 22, 2024 | 153.35M |
| March 21, 2024 | 159.57M |
| March 20, 2024 | 141.24M |
| March 19, 2024 | 133.71M |
| March 18, 2024 | 132.07M |
| March 15, 2024 | 115.70M |
| March 14, 2024 | 137.63M |
| March 13, 2024 | 27.04M |
| March 12, 2024 | 25.61M |
| March 11, 2024 | 5.662M |
| Date | Value |
|---|---|
| March 08, 2024 | 5.682M |
| March 07, 2024 | 6.288M |
| March 06, 2024 | 7.906M |
| March 05, 2024 | 7.502M |
| March 04, 2024 | 7.704M |
| March 01, 2024 | 7.704M |
| February 29, 2024 | 7.299M |
| February 28, 2024 | 7.704M |
| February 27, 2024 | 8.007M |
| February 26, 2024 | 6.288M |
| February 23, 2024 | 7.097M |
| February 22, 2024 | 8.513M |
| February 21, 2024 | 8.108M |
| February 20, 2024 | 8.816M |
| February 16, 2024 | 8.513M |
| February 15, 2024 | 7.502M |
| February 14, 2024 | 7.502M |
| February 13, 2024 | 9.119M |
| February 12, 2024 | 10.94M |
| February 09, 2024 | 9.119M |
| February 08, 2024 | 6.288M |
| February 07, 2024 | 5.378M |
| February 06, 2024 | 3.862M |
| February 05, 2024 | 4.670M |
| February 02, 2024 | 4.873M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-26.85M
Minimum
Jan 24 2022
166.11M
Maximum
Mar 27 2024
12.45M
Average
5.947M
Median
Jan 09 2020
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals Inc | 2.344B |
| ADMA Biologics Inc | 1.444B |
| FibroGen Inc | 7.705M |
| Protara Therapeutics Inc | -33.11M |
| Amylyx Pharmaceuticals Inc | -230.71M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.061M |
| Total Expenses (Quarterly) | 8.30M |
| EPS Diluted (Quarterly) | -0.39 |
| Earnings Yield | -57.04% |
| Normalized Earnings Yield | -198.56 |